Zealand Pharma

Zealand Pharma is an international biotechnology company headquartered in Denmark. Their focus is on the discovery, design, and development of innovative peptide-based medicines, particularly for people with unmet medical needs. They have a strong commitment to creating value for their shareholders and society by delivering life-changing peptide therapeutics. The company focuses on specific disease areas where they believe peptide therapies can have a significant impact, including obesity, congenital hyperinsulinism, short bowel syndrome, chronic inflammation, and type 1 diabetes.

Their research and development efforts are directed towards building a robust pipeline of novel and differentiated peptide candidates. This pipeline includes several promising treatments in various stages of development, such as Petrelintide, Dapiglutide, and ZP6590. The company also prioritizes collaboration and partnering with other organizations to accelerate the development and delivery of their therapies.

Zealand Pharma is a Danish biotechnology company focused on developing innovative peptide-based medicines to address unmet medical needs. They are committed to creating value for society and shareholders through life-changing therapies.

Zealand Pharma fosters a collaborative, courageous, empowering, and trusting work environment. They believe in working together as one team, promoting open communication and encouraging individuals to take initiative and contribute their best.

Zealand Pharma emphasizes a strong and engaging company culture built on collaboration, courage, empowerment, and trust. This is reflected in their approach to diversity, equity and inclusion, where they value the unique perspectives and experiences of their employees. While specific initiatives or programs aren't explicitly mentioned on their website, their commitment to fostering a positive and inclusive work environment is clear, evidenced by their emphasis on teamwork and their diverse team of "Zealanders."